(360 days)
No
The device description and performance studies focus on the material properties and biological integration of a collagen mesh, with no mention of AI or ML technologies.
Yes
Lyograft is intended for implantation to repair, reinforce, and/or supplement soft tissue which aligns with the definition of a therapeutic device.
No
The device description clearly states its intended use is "implantation to repair, reinforce and/or supplement soft tissue," indicating a therapeutic rather than diagnostic function.
No
The device description clearly states it is a biological surgical mesh made of bovine pericardium, which is a physical material, not software. The performance studies also focus on material properties and biological integration, not software performance.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "for implantation to repair, reinforce and/or supplement soft tissue." This describes a device that is surgically implanted into the body for a therapeutic purpose.
- Device Description: The description details a biological surgical mesh made of bovine pericardium, designed for long-term implantation and tissue integration. This is consistent with a surgical implant, not a diagnostic test performed outside the body.
- Lack of Diagnostic Elements: There is no mention of analyzing samples from the body (like blood, urine, tissue) to provide diagnostic information about a patient's health status. IVDs are designed to perform such analyses.
Therefore, Lyograft is a surgical implant, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Lyograft® is intended for implantation to repair, reinforce and/or supplement soft tissue.
Product codes
FTM
Device Description
Lyograft is a biological surgical mesh comprised of pure collagen made of bovine pericardium. It is a single layered membrane of connective tissue with the collagen fibers running in three dimensions. Lyophilization causes the formation of a mesh, free of non-collagenous components, with a loose fibrous structure and large communicating pores. Lyograft is a long-term implant that will be incorporated into the patient's tissue over time.
Lyograft is supplied in various sizes ranging from 8x14cm to 20x30cm. It is provided sterile within a double blister package and is for single use. Lyograft is rehydrated in a physiological saline solution and cut to size using aseptic technique prior to use. It is recommended to suture Lyograft in place using non-absorbable sutures.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
soft tissue, abdominal wall
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Biocompatibility testing: The biocompatibility evaluation for Lyograft was conducted in accordance with ISO 10993-1 "Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing Within a Risk Management Process," as recognized by FDA. Lyograft is considered a long term (>30 days) implant which comes in contact with tissue. The following tests have been considered per the standard: Cytotoxicity, Sensitization, Irritation, Acute Systemic toxicity, Material Mediated Pyrogenicity, Subchronic Toxicity, Chronic Toxicity, Hemolysis, Genotoxicity, Implantation.
Performance Testing - Bench: The following tests were conducted on both the subject and predicate devices to evaluate the performance characteristics and collagen purity: Tensile Strength, Burst Strength, Density Weight/Area, DSC Analysis, FTIR Analysis, Acetic Acid Test, Hydroxyproline Test, Water Content.
Performance Testing - Animal: An animal study comparing the performance of Lyograft and Tutomesh for tissue reinforcement in the abdominal wall and tissue integration in a rabbit model was conducted. Sample size: Sixteen (16) female New Zealand White rabbits were assigned to the following groups: Four (4) rabbits implanted with Lyograft for 12-week explantation and four (4) rabbits implanted with Tutomesh for 12-week explantation; four (4) rabbits implanted with Lyograft for 24-week explantation and four (4) rabbits implanted with Tutomesh for 24-week explantation. Key results: The test (Lyograft) and reference (Tutomesh) samples were cut to a defined size and sutured to the traumatized abdominal wall per standard procedure. The test and reference surgical sites were macroscopically examined after 12 and 24 post-operative weeks subsequently explanted for further histological examination. The results for Lyograft and Tutomesh at both the 12 and 24-week time points showed similar local tissue reaction and tissue integration.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.3300 Surgical mesh.
(a)
Identification. Surgical mesh is a metallic or polymeric screen intended to be implanted to reinforce soft tissue or bone where weakness exists. Examples of surgical mesh are metallic and polymeric mesh for hernia repair, and acetabular and cement restrictor mesh used during orthopedic surgery.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
September 3, 2020
B. Bruan Surgical, SA % Robin Fatzinger Principle Consultant Oreg Consulting, LLC 2192 Martin Drive Gilbertsville, Pennsylvania 19525
Re: K192452
Trade/Device Name: Lyograft Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical Mesh Regulatory Class: Class II Product Code: FTM Dated: July 31, 2020 Received: August 3, 2020
Dear Robin Fatzinger:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
1
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Cindy Chowdhury, Ph.D., M.B.A. Acting Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K192452
Device Name Lyograft
Indications for Use (Describe)
Lyograft® is intended for implantation to repair, reinforce and/or supplement soft tissue.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
5. 510(k) Summary as Required by 21 CFR 807.92(c).
I. SUBMITTER
B. Braun Surgical, S.A. Carretera de Terrassa, 121 08191 Barcelona, Rubí Spain
Phone: +34 935 86 62 00 Fax: +34 935 82 95 77
Contact Person: Pau Turon Dols, Ph.D Director of R&D, Regulatory, & Ouality
Date Prepared: 06 September 2019
II. DEVICE
Name of Device: Lyograft®
Common or Usual Name: Mesh, Surgical
Classification Name: Surgical Mesh (21 CFR 878.3300)
Regulatory Class: II
Product Code: FTM
III. PREDICATE DEVICE
TUTOMESH®, K091142 (B. Braun Surgical, S.A. is not aware of this predicate device being subject to a design-related recall. )
Lyoplant (K970851) and Lyoplant Onlay (K122791) will be used as reference devices to support product safety. Lyoplant and Lyoplant Onlay are dura substitutes (GXQ) which are manufactured from the identical bovine pericardium material by B. Braun Melsungen AG (Carl-Braun-Straße 1 -34212 Melsungen, Germany), the parent company of B. Braun Surgical, S.A.
IV. DEVICE DESCRIPTION
Lyograft is a biological surgical mesh comprised of pure collagen made of bovine pericardium. It is a single layered membrane of connective tissue with the collagen fibers running in three dimensions. Lyophilization causes the formation of a mesh, free of non-collagenous components, with a loose fibrous structure and large communicating pores. Lyograft is a long-term implant that will be incorporated into the patient's tissue over time.
Lyograft is supplied in various sizes ranging from 8x14cm to 20x30cm. It is provided sterile within a double blister package and is for single use. Lyograft is rehydrated in a physiological saline solution and
4
cut to size using aseptic technique prior to use. It is recommended to suture Lyograft in place using nonabsorbable sutures.
V. INDICATIONS FOR USE
Lyograft® is intended for implantation to repair, reinforce and/or supplement soft tissue.
VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
| TUTOMESH® - Predicate | Lyograft® - Subject Device | |
|---|---|---|
| 510(k) Number | K091142 | TBD |
| Device Class | II | II |
| Product Code | FTM | FTM |
| Panel | 878.3300 | 878.3300 |
| Intended Use | General & Plastic Surgery | |
| Implanted to reinforce soft | ||
| tissue or bone where weakness | ||
| exists. | General & Plastic Surgery | |
| Implanted to reinforce soft | ||
| tissue where weakness exists. | ||
| Indications for Use | This device is intended for | |
| implantation to repair, reinforce | ||
| and/or supplement soft tissue. | Lyograft® is intended for | |
| implantation to repair, reinforce | ||
| and/or supplement soft tissue. | ||
| Material Source | Bovine Pericardium | Bovine Pericardium |
| Material Type | Acellular, non-crosslinked, | |
| 3-dimensional Collagen Matrix | Acellular, non-crosslinked, | |
| 3-dimensional Collagen Matrix | ||
| Resorbable | Yes | Yes |
| Shape(s) | Oval | Rectangular |
| Size(s) | 10 x 16cm & 13 x 22cm | 8 x 14cm to 20 x 30cm |
| How Supplied | Double Blister Package | Double Blister Package |
| Sterilization Method | Tutoplast® Tissue Sterilization | |
| Process and Gamma Irradiation | EtO | |
| Reusable | Single Use | Single Use |
5
VII. PERFORMANCE DATA
FDA Guidance for the Preparation of a Premarket Notification for a Surgical Mesh (March 2, 1999) was considered in determining the requirements for demonstrating substantial equivalence to the predicate device. The following performance data were provided in support of the substantial equivalence determination.
Biocompatibility testing
The biocompatibility evaluation for Lyograft was conducted in accordance with ISO 10993-1 "Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing Within a Risk Management Process," as recognized by FDA. Lyograft is considered a long term (>30 days) implant which comes in contact with tissue. The following tests have been considered per the standard:
- Cytotoxicity ●
- Sensitization
- Irritation .
- Acute Systemic toxicity ●
- Material Mediated Pyrogenicity
- Subchronic Toxicity
- Chronic Toxicity
- Hemolysis
- Genotoxicity ●
- Implantation ●
Performance Testing - Bench
The following tests were conducted on both the subject and predicate devices to evaluate the performance characteristics and collagen purity:
- Tensile Strength
- Burst Strength ●
- Density Weight/Area ●
- DSC Analysis ●
- FTIR Analysis
- Acetic Acid Test
- Hydroxyproline Test ●
- Water Content ●
Performance Testing - Animal
An animal study comparing the performance of Lyograft and Tutomesh for tissue reinforcement in the abdominal wall and tissue integration in a rabbit model was conducted. Sixteen (16) female New Zealand White rabbits were assigned to the following groups: Four (4) rabbits implanted with Lyograft for 12week explantation and four (4) rabbits implanted with Tutomesh for 12-week explantation; four (4) rabbits implanted with Lyograft for 24-week explantation and four (4) rabbits implanted with Tutomesh for 24week explantation. The test (Lyograft) and reference (Tutomesh) samples were cut to a defined size and sutured to the traumatized abdominal wall per standard procedure.
6
The test and reference surgical sites were macroscopically examined after 12 and 24 post-operative weeks subsequently explanted for further histological examination. The results for Lyograft and Tutomesh at both the 12 and 24-week time points showed similar local tissue reaction and tissue integration.
VIII. CONCLUSIONS
The subject device, Lyograft, and the predicate device, Tutomesh, are both biological surgical made from bovine pericardium and utilize the same technological characteristics and principles to reinforce soft tissue where weakness exists. The devices have the same biocompatibility safety profile and similar performance as demonstrated in bench and animal testing described above. Any minor differences in performance test results do not raise new issues of safety. Therefore, based on these similarities, Lyograft is considered substantially equivalent to Tutomesh.